EquityNet Research begins independent coverage on Huifeng Bio-Pharmaceutical Technology

Dec 22 2009

Huifeng Bio-Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB), a leading developer and producer of plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production, today reported that after preliminary due diligence, including review of the company's market potential and development opportunities, EquityNet Research is initiating coverage of the company as an independent analyst.

Founded 10 years ago, the Los Angeles, Calif.-based research firm provides the investing public with professional, independent, objective research on under-followed public companies. It does this by preparing detailed research that highlights the key aspects of the company and its industry. Two of the firm's three principals are holders of the Chartered Financial Analyst (CFA) designation.

"Independent research provides a benchmark by which potential investors can gauge a company's fair value, eliminating such extraneous factors as supply and demand issues," said EquityNet Founder and Senior Equity Analyst Randall Lewis. "And perhaps most importantly, it is a statement by management to current shareholders and investors that, 'We have enough confidence in our company and future to compensate an independent analyst to perform a fair, accurate valuation of our stock, just like private companies do all the time.' This shows at least that the company feels it has nothing to hide, and has self-assurance in its business model."

Lewis pointed out that according to a survey by Charles Schwab & Co., reported in The New York Times, an astonishing 78% of active stockholders now "value research from independent firms over analysis by Wall Street firms with financial ties to the companies they are rating..."

EquityNet Research expects to publish its initial coverage of Huifeng Bio-Pharmaceutical in January 2010.